Two cases with generalised bullous cutaneous reactions after COVID-19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®)

DSpace/Manakin Repository

Two cases with generalised bullous cutaneous reactions after COVID-19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®)
 
Rinnooy Kan, Charlotte E.; Röckmann, Heike; van Dijk, Marijke R.; Ramsaransing, Tanuja; Reubsaet, Lieke L.; Peters, Elke E.M.; Vos, Lydia E.
(2024) JEADV Clinical Practice, volume 3, issue 1, pp. 275 - 279
(Article)
Abstract
Bullous cutaneous reactions can be caused by many factors, including vaccines.1 However, among all cutaneous reactions following coronavirus disease 2019 (COVID-19) mRNA vaccines, bullous reactions are rare. Here, we describe two patients with delayed generalised bullous cutaneous reactions 7 days after receiving Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®) COVID-19 vaccination, respectively.
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: bullous cutaneous reaction, bullous eruption, COVID-19 mRNA vaccination, Pfizer and Moderna COVID-19 vaccination, reactive dermatitis, Dermatology
DOI: https://doi.org/10.1002/jvc2.273
ISSN: 2768-6566
Publisher: John Wiley & Sons Inc.
Note: Publisher Copyright: © 2023 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
(Peer reviewed)